CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies

被引：173

作者：

Beers, Stephen A. ^{[1
]}

Chan, Claude H. T. ^{[1
]}

French, Ruth R. ^{[1
]}

Cragg, Mark S. ^{[1
]}

Glennie, Martin J. ^{[1
]}

机构：

[1] Univ Southampton, Sch Med, Gen Hosp, Tenovus Lab,Canc Sci Div, Southampton SO16 6YD, Hants, England

来源：

SEMINARS IN HEMATOLOGY | 2010年 / 47卷 / 02期

基金：

英国医学研究理事会;

关键词：

CELL ANTIGEN RECEPTOR; MHC CLASS-II; SURFACE ANTIGEN; LYMPHOMA-CELLS; B-LYMPHOCYTES; RITUXIMAB; ACTIVATION; REDISTRIBUTION; MECHANISMS; EXPRESSION;

D O I：

10.1053/j.seminhematol.2010.01.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The last decade has seen the monoclonal antibody (mAb), rituximab, transform clinical management of many non-Hodgkin lymphomas and more recently provide new opportunities for controlling autoimmune conditions, such as rheumatoid arthritis. Although not yet fully determined, the explanation for this success appears to lie with the inherent properties of its target, CD20, which allow rituximab to recruit potent cytotoxic effectors with unusual efficiency. In this review we detail the properties of CD20 that make it such an effective therapeutic target and describe how different mAbs change the membrane distribution and internalization of CD20 and have distinct modes of cytotoxic activity. Semin Hematol 47:107-114. (C) 2010 Published by Elsevier Inc.

引用

页码：107 / 114

页数：8

共 60 条

[1] Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin [J].